Protein Summary
Exhibits PLA1/2 activity, catalyzing the calcium-independent hydrolysis of acyl groups in various phosphatidylcholines (PC) and phosphatidylethanolamine (PE). For most substrates, PLA1 activity is much higher than PLA2 activity. Catalyzes N-acylation of PE using both sn-1 and sn-2 palmitoyl groups of PC as acyl donor. Also catalyzes O-acylation converting lyso-PC into PC. The protein encoded by this gene has both phospholipase and acyltransferase activities and acts as a tumor suppressor. The encoded protein can hydrolyze dipalmitoylated phosphatidylcholine (PC) to palmitic acid and lyso-PC. In addition, this protein can catalyze the N-acylation of phosphatidylethanolamine and can catalyze the O-acylation of lyso-PC to form PC. [provided by RefSeq, Jul 2016]
- ENST00000255695
- ENSP00000255695
- ENSG00000133328
- HRASLS2
- PLAAT-2
- PLA1/2-2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
cell type or tissue | 0.85 | ||
tissue | 0.57 | ||
metabolite | 0.45 | ||
small molecule perturbation | 0.39 | ||
phenotype | 0.38 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 3.78 (req: < 5)
Gene RIFs: 5 (req: <= 3)
Antibodies: 86 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 3.78 (req: >= 5)
Gene RIFs: 5 (req: > 3)
Antibodies: 86 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 4
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 10
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0